Clinical Scorecard: The Influence of Transplant Center Volume on Pediatric Outcomes in Allogeneic Hematopoietic Cell Transplantation
At a Glance
Category
Detail
Condition
Pediatric patients undergoing allogeneic hematopoietic cell transplantation (HCT) for malignant and non-malignant diseases
Key Mechanisms
Center volume effect on transplant outcomes potentially mediated by institutional experience, conditioning regimens, immunosuppression, and supportive care practices
Target Population
Pediatric patients aged 19 years or younger receiving first allogeneic HCT
Care Setting
Pediatric transplant centers categorized by allogeneic HCT volume over 20 years
Key Highlights
No statistically significant difference in 5-year overall survival (OS) across transplant center volume categories (low to high volume centers).
High-volume centers had a higher proportion of non-malignant disease transplants, fewer umbilical cord blood transplants, and more non-myeloablative conditioning.
Previous studies on center volume effects in pediatric HCT are limited and findings are inconsistent, highlighting the need for pediatric-specific analyses.
Guideline-Based Recommendations
Diagnosis
Include pediatric patients aged ≤19 years undergoing first allogeneic HCT for malignant or non-malignant diseases.
Exclude patients from mixed pediatric-adult teams and those receiving allogeneic transplants for solid tumors.
Management
Optimize conditioning regimens and donor matching tailored to patient disease and center experience.
Implement supportive care protocols to manage post-transplant immune responses and complications.
Monitoring & Follow-up
Use Kaplan-Meier and cumulative incidence methods to monitor overall survival, relapse, and non-relapse mortality.
Perform multivariate Cox regression analyses to adjust for confounding factors in outcome assessment.
Risks
Recognize that factors such as disease type and residual tumor burden impact outcomes beyond center control.
Consider that high-volume centers may treat more complex or higher-risk patients, potentially influencing outcomes.
Patient & Prescribing Data
Pediatric patients undergoing first allogeneic HCT at pediatric centers in Japan from 2001 to 2020
Center volume did not significantly affect 5-year overall survival; treatment approaches varied with center volume, including conditioning intensity and graft source selection.
Clinical Best Practices
Classify transplant centers by cumulative allogeneic HCT volume to evaluate institutional experience.
Tailor conditioning regimens and supportive care based on center expertise and patient disease characteristics.
Utilize nationwide registry data for comprehensive outcome analysis and quality improvement.
Ensure ethical compliance and informed consent for use of clinical data in research.
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
